Adjuvant treatment of colorectal cancer at the turn of the century European and US perspectives

Annals of Oncology

Volumn 12, Issue 1, 2001, Pages 13-22

  Wils, J ^a   O'Dwyer, P ^b   Labianca, R ^c  

^a LAURENTIUS HOSPITAL   (Netherlands)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Riuniti Hospital   (Italy)

Author keywords

Adjuvant treatment; Colorectal cancer; PETACC

Indexed keywords

5 ETHYNYLURACIL; ALPHA2A INTERFERON; CAPECITABINE; CYTOTOXIC AGENT; EDRECOLOMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PLACEBO; RALTITREXED; SEMUSTINE; UFT; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; EUROPE; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MEDICAL LITERATURE; NORTH AMERICA; PORTAL VEIN; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; TREATMENT OUTCOME; UNITED STATES;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; EUROPE; FLUOROURACIL; HUMANS; INTERNATIONAL COOPERATION; LEUCOVORIN; PHYSICIAN'S PRACTICE PATTERNS; RADIOTHERAPY, ADJUVANT; UNITED STATES;

EID: 0035135578     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008357725209     Document Type: Review

References (72)

1. Colorectal cancer
2. 2 and C colorectal cancer
3. Prolongation of disease-free interval in surgically treated rectal carcinoma
4. Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel
5. Lack of effectiveness of 5-FU & methyl CCNU as compared to 5-FU for adjuvant therapy in colon cancer: A randomized trial of the Eastern Cooperative Oncology Group
6. Adjuvant therapy in large bowel adenocarcinoma: Long-term results of a Southwest Oncology Group study
7. Surgical adjuvant therapy of large-bowel carcinoma. An evaluation of levamisole and the combination of levamisole and fluorouracil
8. Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01
9. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
10. Adjuvant treatment of colon cancer: Where to go from here?
11. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon cancer: A final report
12. Controlled trial of fluorouracil and low-dose leucovorin given for six months as postoperative adjuvant therapy for colon cancer
13. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer
14. Adjuvant 5FU plus levamisone improves survival in stage II and III colonic cancer, but not in rectal cancer. Interim analysis of the Netherlands Adjuvant Colorectal Cancer Project (NACCP)
15. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
16. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03
17. Mechanism of synergy of levamisole and fluorouracil: Induction of human leucocyte antigen class I in a colorectal cancer cell line
18. Enigma of fluorouracil and levamisole
19. A randomised trial of adjuvant therapy of stage III colon cancer. Levamisole and 5-fluorouracil versus 5-fluorouracil alone
20. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Surgical Adjuvant Breast and Bowel Project C-04
21. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089
22. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
23. The relative efficacy of 5-FU - Leucovorin (FU-LV) and 5-FU-LV + interferon-α2a (IFN) in patients with Dukes' B and C carcinoma of the colon: First report of NSABP C-05
24. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial
25. Phase III randomized trial of bolus 5-FU-leucovorin-levamisole versus 5-FU continuous infusion-levamisole as adjuvant therapy for high-risk colon cancer (SWOG 9415/INT-0153)
26. Multicentre randomized trial of protracted venous infusion (PVI) 5-FU compared to 5-FU-folinic acid (5-FU-FA) as adjuvant therapy for colorectal cancer
27. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
28. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
29. The tea leaves of small trials
30. Active specific immunotherapy for stage II and III human colon cancer: A randomized trial
31. Micrometastases and survival in stage II colorectal cancer
32. Accuracy of diagnosis of micrometastases in colorectal cancer (CRCa) by sentinel lymph node (SLN) mapping technique
33. In vivo kinetic of thymidylate synthase inhibition in 5-fluorouracil-sensitive and resistant murine colon adenocarcinomas
34. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast disease
35. Thymidylate synthase: A target enzyme in cancer chemotherapy
36. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
37. Quantification of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
38. Adjuvant cytotoxic liver perfusion for colorectal cancer
39. Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality
40. Adjuvant portal vein infusion for colorectal cancer: A three-arm randomized trial
41. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracilheparin versus urokinase versus control
42. Adjuvant therapy of Dukes' A, B and C adenocarcinoma of the colon with portalvein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02
43. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion
44. Randomized controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma
45. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer
46. Portal vein chemotherapy for colorectal cancer: A meta-analysis of 4000 patients in 10 studies
47. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: A randomized trial
48. Intraportal 5-FU (PVI) and peri-operative radiotherapy (RT) in the adjuvant treatment of colorectal cancer (CRCa)-3681 patients randomized in the UK Coordinating Committee on Cancer Research (UKCCCR) AXIS trial
49. Randomized trial of adjuvant perioperative chemotherapy in radically resected colorectal cancer (SAKK 40/87)
50. A randomized trial of intraportal (IP) versus systemic (SY) versus IP + SY adjuvant chemotherapy in patients (pts) with resected Dukes B-C colon carcinoma (CC)
51. Adjuvant treatment of colon cancer. A plea for a large-scale European trial
52. The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer
53. Phase III multicenter randomized trial of oxaliplatin addition to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
54. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
55. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A randomised trial
56. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
57. Adjuvant Therapy of Rectal Cancer
58. Effective surgical adjuvant therapy for high-risk rectal carcinoma
59. Survival after postoperative combination treatment of rectal cancer
60. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01
61. A comparison of post-operative adjuvant chemotherapy, radiotherapy or combination therapy in potentially curable resectable rectal carcinoma
62. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery
63. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum
64. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project protocol R-02
65. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of Intergroup 0114
66. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC)
67. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prosperative randomized trial
68. Improved survival with preoperative radiotherapy in resectable rectal cancer
69. Adjuvant therapy for rectal cancer - A good first step
70. Combined modality adjuvant treatment of high-risk rectal cancer: A treatment of choice or a choice of treatment?
71. Adjuvant chemotherapy in colorectal carcinoma. Results of a meta-analysis
72. Drug-company decision to end cancer trial